

Thursday, April 4th 2019 Professional Development Day

10:00 – 10:15 AM	Pre-test	All
10:15 – 11:15 AM	Handling Hazardous Drugs: USP 800 Updates (Law CE)	Sally Habusta PharmD <i>Sanofi Post-Doctoral Fellow</i> and Hamza Sarwar PharmD <i>Sanofi Post-Doctoral Fellow</i>
11:15 – 11:30	BREAK	
11:30 – 11:55 AM	Digital Therapeutics: reSET[®] App	Michael Severo PharmD <i>Novartis Post-Doctoral Fellow</i>
11:55 – 12:20 PM	Clinical breakthrough: siRNA to Treat Polyneuropathy Associated with Hereditary Transthyretin-mediated Amyloidosis	Anastasiya Koshkina PharmD <i>Johnson & Johnson/Actelion Post-Doctoral Fellow</i>
12:20 – 1:20 PM	LUNCH	
1:20 – 1:25 PM	Five Minutes With	
1:25 – 1:50 PM	Targeted Treatment Fields in Oncology: The Optune[®] Wearable Device	Kelly Chambers PharmD <i>Merck Post-Doctoral Fellow</i>
1:50 – 2:15 PM	Sickle Cell Anemia, New and Innovative Treatment Updates for the Pharmacist	Stephen Agyenim-Boateng PharmD, RPh <i>Bayer Post-Doctoral Fellow</i>
2:15 – 2:30 PM	BREAK	
2:30 – 2:55 PM	OTC Naloxone is Coming, Are You Ready for it?	Julia Spiridigliozzi PharmD <i>Merck Post-Doctoral Fellow</i>
2:55 – 3:05 PM	Question and Answer	ALL
3:05 – 3:20 PM	Post-test	All
3:20 – 3:30 PM	Closing Remarks	Dean Barone, Dr. Toscani, Dr. Fierro and Co-Chiefs

Objectives

- Summarize the clinical use of patisiran (Onpattro) in hATTR
- Determine what The Optune means for the future of cancer treatment
- Review the need and usage for Naloxone
- Identify current treatment options for substance use disorders (SUDs) and evaluate place in therapy for reSET[®]
- Summarize therapies and the pharmacist's role in sickle cell disease treatment and management
- Distinguish the regulating bodies and regulations that govern 503A and 503B compounding pharmacies.
- Determine the mandatory facility and engineering controls defined in USP 800 and apply those to a



JOINTLY ACCREDITED PROVIDER[™]
INTERPROFESSIONAL CONTINUING EDUCATION

- This activity is designed for Pharmacists, other Health Care Professionals and other Stakeholders. This program is organized by Rutgers Ernest Mario School of Pharmacy. All individuals who affect the content of continuing education activities are required to disclose to the audience any real or apparent conflict of interest related to the activity. The activity faculty are further required to disclose discussion of off-label/investigational uses in their presentations. These disclosures will be made to the audience at the time of the activity.
- Requirements for completion - Pharmacists must be in attendance for the entire program. All attendees MUST sign in and complete a pre-test/post-test and program evaluation in order to receive program credit. No partial credit will be awarded.
- Pharmacists: Your NABP e-Profile ID and date of birth will be collected at the conclusion of the program. CPE credit will be processed after the program evaluation has closed to participants, which will be three to four weeks following the activity date.
- For additional program information, questions, or concerns, or if you require special arrangements to attend this activity, please contact RBHS Ernest Mario School of Pharmacy Office of Continuing Education, Debra Diller at 848-445-6823 or ddiller@pharmacy.rutgers.edu
- RBHS reserves the right to modify the activity content, faculty and activities, and reserves the right to cancel this activity, if necessary. For additional program information, questions, or concerns, or if you require special arrangements to attend this activity, please contact RBHS Ernest Mario School of Pharmacy Office of Continuing Education, Debra Diller at 848-445-6823